NeuroMetrix Reports Q1 2022 Financial Results
NeuroMetrix (NURO) reported Q1 2022 revenue of $2.3 million, a 6.8% increase from the previous year, driven by a 15.6% growth in DPNCheck® sales to Medicare Advantage. The gross margin improved to 77.9% from 73.3%. However, operating expenses rose to $2.8 million from $1.6 million, leading to a net loss of $959,000 (or $0.14 per share). The company ended the quarter with $23.8 million in cash and equivalents. Notably, Quell® technology received FDA Breakthrough Designation for chronic chemotherapy-induced neuropathy.
- Q1 2022 revenue increased by 6.8% to $2.3 million.
- DPNCheck® sales into Medicare Advantage grew by 15.6% year-on-year.
- Gross margin improved to 77.9% from 73.3% in the previous year.
- Cash and equivalents at $23.8 million provide ample liquidity.
- FDA Breakthrough Designation for Quell® technology.
- Operating expenses increased significantly to $2.8 million.
- Net loss of $959,000 or $0.14 per share.
WOBURN, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended March 31, 2022. The Company's mission is to reduce the impact of neurological disorders and pain syndromes on individuals and on population health through innovative non-invasive medical devices.
Highlights:
- Q1 2022 revenue of
$2.3 million increased by6.8% from$2.2 million in the prior year. DPNCheck® sales into Medicare Advantage were the primary contributor to revenue and posted15.6% year-on-year growth. The gross margin rate was77.9% in Q1 2022 versus73.3% in Q1 2021. - Operating expenses were
$2.8 million versus$1.6 million in Q1 2021. Sales & marketing and general & administrative spending increased to support the Company's growth initiatives. Also, prior year R&D expenses benefited from the reversal of a previously accrued technology fee of$450 thousand . - Net loss for the quarter was
$959 thousand or ($0.14) per share - The Company ended the quarter with cash and equivalents of
$23.8 million - In January the Company’s Quell® technology received Breakthrough Designation from the U.S. Food and Drug Administration (FDA) for treatment of chronic chemotherapy induced peripheral neuropathy (CIPN).
- The Company's value-based health care commercial team grew to 4 uniquely experienced sales, marketing and clinical leaders.
“Our value-based care commercial team is now fully trained and focused on building our DPNCheck® Medicare Advantage business. Although the sales cycle is long, they have had impressive success engaging existing and prospective customers,” said Shai N. Gozani, M.D., Ph.D., Chief Executive Officer of NeuroMetrix. “We are also encouraged by progress in our Quell prescription neurotherapeutics platform. We are interacting with the FDA on the fibromyalgia De Novo request and monitoring randomized controlled trials evaluating potential new indications including CIPN and post-acute sequalae of COVID (long COVID).”
Financials:
Q1 2022 revenue of
Company to Host Live Conference Call and Webcast
NeuroMetrix will host a conference call at 8:00 a.m. Eastern today, April 26, 2022. The call may be accessed in the United States at 844-787-0799, international at 661-378-9630 using confirmation code 5754338. A replay will be available starting two hours after the call at 855-859-2056 United States and 404-537-3406 international using confirmation code 5754338. It will remain available for one week. The call will also be webcast and accessible at www.NeuroMetrix.com under "Investor Relations".
About NeuroMetrix
NeuroMetrix is an innovation-driven company focused on the development and global commercialization of non-invasive medical devices for the diagnosis and treatment of pain and neurological disorders. The Company has three commercial products. DPNCheck® is a diagnostic device that provides rapid, point-of-care detection of peripheral neuropathies. ADVANCE® is a diagnostic device that provides automated, in-office nerve conduction studies for the evaluation of focal neuropathies. Quell® is a wearable neurostimulation device indicated for symptomatic relief of lower extremity chronic pain that is available over-the-counter. For more information, visit www.NeuroMetrix.com.
Safe Harbor Statement
The statements contained in this press release include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, without limitation, statements regarding the company’s or management’s expectations regarding the business, as well as events that could have a meaningful impact on the company’s revenues and cash resources. While the company believes the forward-looking statements contained in this press release are accurate, there are a number of factors that could cause actual events or results to differ materially from those indicated by such forward-looking statements, including, without limitation, the effects of the COVID-19 pandemic on all aspects of the Company’s business, estimates of future performance, and the ability to successfully develop, receive regulatory clearance, commercialize and achieve market acceptance for any products. There can be no assurance that future developments will be those that the company has anticipated. Such forward-looking statements involve known and unknown risks, uncertainties and other factors including those risks, uncertainties and factors referred to in the company’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, as well as other documents that may be filed from time to time with the Securities and Exchange Commission or otherwise made public. The company is providing the information in this press release only as of the date hereof, and expressly disclaims any intent or obligation to update the information included in this press release or revise any forward-looking statements.
Source: NeuroMetrix, Inc.
Thomas T. Higgins
SVP and Chief Financial Officer
781-314-2761
neurometrix.ir@neurometrix.com
| NeuroMetrix, Inc. Statements of Operations (Unaudited) | ||||||||
| Quarters Ended March 31, | ||||||||
| 2022 | 2021 | |||||||
| Revenues | $ | 2,302,391 | $ | 2,155,472 | ||||
| Cost of revenues | 508,874 | 576,289 | ||||||
| Gross profit | 1,793,517 | 1,579,183 | ||||||
| Operating expenses: | ||||||||
| Research and development | 710,577 | 233,277 | ||||||
| Sales and marketing | 858,839 | 393,825 | ||||||
| General and administrative | 1,186,091 | 1,012,276 | ||||||
| Total operating expenses | 2,755,507 | 1,639,378 | ||||||
| Loss from operations | (961,990 | ) | (60,195 | ) | ||||
| Other income | 3,428 | 412 | ||||||
| Net loss | $ | (958,562 | ) | $ | (59,783 | ) | ||
| NeuroMetrix, Inc. Condensed Balance Sheets (Unaudited) | ||||||||
| March 31, 2022 | December 31, 2021 | |||||||
| Cash and cash equivalents | $ | 23,769,380 | $ | 22,572,104 | ||||
| Other current assets | 1,817,871 | 1,615,755 | ||||||
| Noncurrent assets | 661,120 | 700,333 | ||||||
| Total assets | $ | 26,248,371 | $ | 24,888,192 | ||||
| Current liabilities | $ | 1,727,254 | $ | 1,365,697 | ||||
| Lease obligation, net of current portion | 283,209 | 306,709 | ||||||
| Stockholders’ equity | 24,237,908 | 23,215,786 | ||||||
| Total liabilities and stockholders’ equity | $ | 26,248,371 | $ | 24,888,192 | ||||
FAQ
What were the earnings results for NeuroMetrix (NURO) in Q1 2022?
How much cash did NeuroMetrix (NURO) have at the end of Q1 2022?
What was the main contributor to revenue growth for NeuroMetrix (NURO) in Q1 2022?
What are the key highlights from NeuroMetrix's (NURO) Q1 2022 financial report?
Did NeuroMetrix (NURO) receive any regulatory approvals recently?
